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ABSTRACT
Objective: This study aims to assess the cost utility of Brivaracetam compared with the third-generation
anti-epileptic drugs used as standard care.
Methods: A cost utility analysis of Brivaracetam was carried out with other third-generation compara-
tors. The treatment pathway of a hypothetical cohort over a period of 2 years was simulated using the
Markov model. Data for effectiveness and the QALYs of each health status for epilepsy, as well as for the
disutilities of adverse events of treatments, were analyzed through a studies review. The cost of the
anti-epileptics and the use of medical resources linked to the different health statuses were taken into
consideration. A probabilistic sensitivity analysis was performed using a Monte Carlo simulation.
Results: Brivaracetam was shown to be the dominant alternative, with Incremental Cost Utility Ratio
(ICUR) values from −11,318 for Lacosamide to −128,482 for Zonisamide. The probabilistic sensitivity
analysis validates these results. The ICUR sensitivity is greater for increases in the price of Brivaracetam
than for decreases, and for Eslicarbizapine over the other adjunctives considered in the analysis.
Conclusions: Treatment with Brivaracetam resulted in cost effective and incremental quality adjusted
life years come at an acceptable cost.
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Q2 �1.�Expert opinion section
Epilepsy is among the most common neurological disorders,
with a global prevalence of almost 50 million [1] and an
annual incidence of 50.4 per 100,000 persons [2], higher for
low- and middle-income countries (81.7/100,000 inhabitants)
than for high-income countries (45.0/100.000 inhabitants).
Patients with epilepsy suffer a multidimensional deteriora-
tion in their quality of life that has negative effects in aspects
such as education, employment, and driving vehicles, as well
as being affected in the functions of daily life, given that those
who manage to control the disorder through medication suf-
fer from tiredness and problems of memory and concentration
among others [3] as well as having a higher probability of
early death than the rest of the population [4].
As a simplistic analysis, there are two types of epileptic
seizures – generalized (involving the whole surface of the
brain simultaneously) and focal (beginning in one part of the
brain). The second type, partial-onset seizures (POS), have
more prevalence, accounting for 60% of the epileptic patients
in Spain [5].
The most common treatment is therapy with oral anti-
epileptics (AED). These AEDs have evolved, and the newer
generations are safer and better tolerated by patients. This
pharmacological treatment begins with monotherapy,
although this does not result in adequate control for the
30% of patients [6,7] who suffer from more persistent or
refractory epilepsy [8]. For patients with this condition an
adjunctive therapy (add-on) is introduced as part of their
maintenance therapy. The add-on choice is based on effec-
tiveness (control of seizures, less seizures), tolerability profile,
and low-risk drugs-interaction. In the case of patients who
suffer from persistent seizures or chronic medicinal adverse
effects, treatments that are apparently more ‘aggressive’, such
as surgery, should be considered [9].
Nowadays there are more than 20 AEDs available for the
treatment of epilepsy, from first to third-generation. Some of
these have numerous side effects and interactions that can
complicate patient treatment and management, especially for
those with refractory epilepsy. The lack of knowledge of the
causes of epileptic seizures makes the choice of medication
difficult, and it is hoped that advances in genome analysis
provide better understanding of AED applicability in patients
[7]. Also ketogenic dietis an alternative therapeutic approach
to antiepileptic drug refractoriness [10].
Brivaracetam (BRV) [11] is one of the third-generation AEDs
being used as an adjunctive drug for patients between 16 and
65 years old with POS, approved in Spain in January 2016 [12].
BRV is a derivative of levetiracetam but exhibits a 20-fold
higher affinity and a faster brain entry time as a synaptic
vesicle glycoprotein 2A (SV2A) ligand. An additional advan-
tage compared to other third generation AEDs is that BRV is
available as an intravenous formulation providing fast pene-
tration into the brain [13].
C
The aim of this study is to perform a cost utility analysis of
BRV compared with the other AEDs used as adjunctives in the
treatment of epilepsy. Specifically, comparison was with the
following third generation AEDs: Eslicarbazepine, Lacosamide,
Perampanel, and Zonisamide and the relation between cost
increment and quality of life increment was determined for
the different treatments.
2. Methods
2.1. Design and analysis perspective
A Markov model was developed using healthcare system and
societal perspectives for the cost utility study of BRV with
regard to the AED comparators used as adjunctives in patients
over 16 diagnosed with POS. This model simulated the pre-
dicted changes in health status according to the transition
probabilities of each AED within a time horizon of 8 trimesters.
Transition probabilities were obtained from randomized-
controlled trials that reported the percentage of patients
who had partial (>50% reduction in seizure frequency) and
complete responses, and the percentage of patients who dis-
continued treatment for any reason. Figure 1 represents the
clinical pathway which is fundamental, given that the Markov
models are structured around health statuses and movements
between them.
Utility was expressed in terms of quality-adjusted life years
(QALYs). Adverse effects of the treatments were taken into
account as regards the disutilities produced. The expenditure
was obtained from the costs of the different AEDs and costs
derived from the use of resources implied by the different
health statuses.
The main assessment metric is the incremental cost utility
ratio (ICUR) of BRV acting as add-on compared with each of
the other drugs. The cost effectiveness analysis was under-
taken from the perspective of the National Health System.
2.2. Treatment strategies
The treatments compared with BRV are 3rd generation AEDs,
specifically: Eslicarbazepine, Lacosamide, Perampanel, and
Zonisamide. These comparators are the most recent approved
treatments. Neither Pregabalin nor Tiagabine were included as
their use as an add-on treatment in Spain is infrequent.
Retigabine, one of the second-generation AEDs used as an
add-on, was originally part of our comparator data [14]. As the
data used is from retrospective observations and this AED was
taken off the market on the 3rd of October 2016, it was
decided to remove Retigabine from our data pool in order
not to interfere in extrapolated results. The manufacturer of
Retigabine, GlaxoSmithKline, announced a permanent stop to
the manufacturing of this drug from June 2017 due to com-
mercial reasons. In 2013, the Food and Drug Administration
(FDA) had warned the public that this drug could cause blue
skin discoloration and eye abnormalities characterized by pig-
ment changes in the retina. These Adverse Events (AEs) are
still being studied; currently the FDA does not know if these
changes are reversible.
2.3. Transition probabilities
The response to treatments, or effectiveness, is measured
through the transition probabilities that predict how people
will move from one health status to another according to the
medication administered. These are fundamental in
Figure 1. Markov chain model.
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determining how patients evolve in the model as the cycles
progress. Moreover, the different AEDs can produce various
adverse effects, with the most common being considered in
this study, which are: ataxia, dizziness, fatigue, nausea, and
somnolence (Table 1). These transition probabilities for each of
the treatments were obtained from the Global Cost-
Effectiveness and Disease Pathway Model for Epilepsy:
Technical Report (Mishra et al. 2015), which in turn is taken
from the Net Meta-analysis NMA carried out by the UCB
laboratory. This report compares BRV, used as adjunctive ther-
apy, to other specified AEDs, and can thus be used to provide
evidence of comparative effectiveness. Bayesian NMAs were
performed for each result using Markov Chain Monte Carlo
(MCMC) methods. This approach combines previous distribu-
tions with observed data to create a back distribution as
a basis for summary results [15]. As the transition probabilities
of each treatment were calculated taking into account an
annual scope, to convert them to 4 periods (n = 4) of
3-months (the usual follow-up period for chronic diseases,
with neurologist visits and other examinations if needed) we
used the Eigendecomposition approach [16].
2.4. Utility data
To measure utility, the QALYs of each health status [17] were
used, together with the utility reduction for each adverse
event [18]. The values were obtained from the study by
Mulhern et al. (2014) carried out on 1,611 patients treated
with different AEDs in monotherapy over a period of 2 years.
The values of these utilities are shown in Table 2. It can be
seen that the probabilities of presenting adverse effects act as
disutilities, or a decrease in the quality of life of the patients,
and were obtained from the work of Vera-Llonch et al [19].
2.5. Cost estimation
The treatment costs were calculated on the basis of the daily
cost of the treatments according to the recommended dosage
for each drug (Table 2). In addition, the costs of health service
use were also taken into account, as well as others implied in
the treatment of the disorder, such as: in-patient care, emer-
gency visits, outpatient visits to the neurologist, visits to the
general practitioner and electroencephalograms. For these
costs, it is considered that the probability of resource use by
the patient varies according to whether they are seizure-free,
have achieved a reduction of 50% in seizures, or have either
not responded to or have stopped treatment for some reason
(Table 3). The trimestral costs were obtained from the fre-
quency of health service use according to the health status
of the patient, the unit cost of each service and the mean
number of seizures suffered by the patient.
2.6. Incremental cost utility ratio (ICUR)
The outcome of the cost utility analysis is presented as an
incremental cost utility ratio (ICUR). The ICUR measures the
incremental cost divided by the incremental utility of each









C2 is the cost under BRV
Table 1. Transition probabilities of each adjunctive treatment (AT) and adverse events annual probabilities.
Effectiveness of each AT
Brivaracetam Eslicarbazepine Lacosamide Perampanel Zonisamide
Responders
(Seizure-free)
0.065 0.032 0.03 0.035 0.018
Partial Responders
(50% Response)
0.355 0.33 0.308 0.296 0.335
Non-responders
(1-(others probability))
0.370 0.469 0.448 0.493 0.47
Discontinuation
(any reason)
0.210 0.169 0.214 0.176 0.177
Adverse Events
Brivaracetam Eslicarbazepine Lacosamide Perampanel Zonisamide
Ataxia 0.03 0.06 0.08 0.04 0.031
Dizziness 0.13 0.23 0.24 0.23 0.088
Fatigue 0.11 0.06 0.06 0.07 0.054
Nausea 0.05 0.12 0.11 0.01 0.053
Somnolence 0.14 0.12 0.1 0.14 0.078
Table 2. Drug cost (Daily cost €), utility of each patient’s health status and utility
reduction of each adverse events.






Patients Health Status Utility
Seizure-free 0.869
Partial-Response (Reduction 50% seizures) 0.805
Non – responder 0.683
Adverse Events Utility reduction





Average cost of concomitant monotherapy (CZP, LMT, OXC, TPR, VAL): 0, 60 €
per day.
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U2 is the effectiveness under BRV
C1 is the cost under the comparator
U1 is the effectiveness under comparator
The cost utility plane shows the results obtained for each
AED compared to BRV. The y-axis shows the cost difference
while the x-axis shows the utility difference. The position on
this plane gives the dominance of the anti-epileptic.
These ICUR analyses were performed through the Markov
chain model, a model well suited for use in epilepsy, as it can
integrate the time factor. The Markov model represents the
natural evolution of epilepsy considering the health status
changes (Figure 1) and adverse events relating these with
cost-utility for each treatment with a two year time horizon
and trimestral cycle length (a total of 8 trimesters), where the
patients are transiting from one status to another or are
maintained stable.
The cost effectiveness or cost utility analysis requires
a modeling to be carried out as a systematic focus for decision
making in uncertain conditions where the probability of every
possible event, together with their consequences, is explicitly
established. Decision trees are the most useful type of decision
modeling when health events happen close together and do not
repeat, when health events happen quickly or not at all, and
when uncertainty over the effects of treatment is resolved
quickly. Markov models are more complex than decisions trees.
They enable us to address a wide range of questions, and
furthermore can explicitly take account of time. This is especially
useful in chronic diseases, as the clinical evolution of patients and
their health status, can pass through different stages over time.
The simulation Markov model was made using Microsoft
Excel and was provided with: 1) treatment effectiveness (tran-
sition probabilities of responding to each treatment); 2) treat-
ment cost; 3) utility (QALYs weight).
The data obtained is based on a specified cohort of 1
patient. These calculations, as before, were performed for 8
cycles, each of three months.
As the time horizon for the study was over one year, the
economic evaluation was conducted with a discount rate of 3
%. This was applied to both costs and health effects as recom-
mended [20].
2.7. Sensitivity analyses
The one way sensitivity analysis only determines the influence
of price variation of BRV on the results of the analysis. The
probabilistic sensitivity analysis (PSA), however, evaluates the
effect of the simultaneous variation of the different para-
meters introduced into the model in the results of the cost
utility analysis of BRV compared to the other AEDs.
This uses the random change of variables, in which the
model is based on studying the impact of each of these on
the results.
To calculate the PSA the β statistical distribution (values
0–1 range) is used for random calculation of the effectiveness
of treatments, and the lognormal statistical distribution for
random calculation of the cost.
The β statistical distribution depends on the parameters (α,
β). QALY weights assume that α = μ*n where µ is the mean
and n is the number of observations and β = (1 − μ) n.
However, health costs supposedly follow a lognormal distribu-
tion instead of a β distribution as QALY weights.
The sensitivity analysis was carried out through a Monte
Carlo simulation, a computerized mathematical technique that
randomly determines the possible results of the analysis from
the variables used as input (cost) and output (utility),
Table 3. Healthcare costs.
Probability of service use
Seizure free Partial response
(50% reduction)
Non- responder Discontinuation
Service 6 months use 6 months use 6 months use 6 months use
Inpatient care (%) 0.30% 0.30% 0.30% 0.30%
Emergency visit (%) 0.80% 0.80% 0.80% 0.80%
Outpatient visit to neurologist 0.75 0.82 1.02 4.52
GP visit 0.08 0.14 0.34 0.14










Seizure free Partial response
(50% reduction)
Non- responder Discontinuation
Service 0 40 160 160
Inpatient care 0 244 974 974
Emergency visit 0 65 259 259
Outpatient visit to neurologist 69 76 94 419
GP visit 7 13 31 13
EEG 16,578 16,578 0 0
6 months cost 93 413 1.358 1.665
3 months cost 47 207 679 832
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randomly extracted from the possible values allowed accord-
ing to the distribution function from which they come.
The impact of the health status switching threshold was
tested separately, with each AED medication determining the
treatment duration for each intervention in the model. The
BRV as add-on treatment effectiveness on clinical parameters
was applied for the treatment period of 1 and 2 years. The
effect of having fewer seizures was expected to be an impor-
tant driver of the cost effectiveness and cost utility results,
given the impact of the adjunctive drug on patients’ AED




Table 4 shows the results for effectiveness, utility, and cost for
each AED, as well as the incremental values for BRV compared
to the alternative adjunctive treatments applied to a single
patient and the ICUR and ICER ratios.
The ICUR goes from −128,482 to −11,318 € per QALY
gained and the ICER goes from −12,827 to −3,817 € per
QALY gained.
Figure 2 simultaneously shows the points of increase in
effectiveness and in utility compared with the increase in
cost for patients treated with BRV compared to the other
AEDs referred to in the study. It can be seen that both series
of points are represented in the lower right quadrant, which
means that it gives better results both regarding effectiveness
and utility and a lower cost.
The reduction in differences in results is greater when
considering effectiveness than utility, due to the units of
measurement. In the case of Zonisamide, the greatest differ-
ence in results is seen according to whether effectiveness or
utility is being evaluated, as the improvement in utility is
much lower than the improvement in effectiveness, which
may be due to the disutilities connected to the adverse
effects, although it is still positive and the cost savings are
evident. As can be seen in Table 2, BRV has a greater prob-
ability of adverse effects than Zonisamide, with the latter
slightly higher only in the case of ataxia and nausea.
Figure 2 shows that Eslicarbizapine is the treatment closest
in cost utility and cost effectiveness to BRV.
3.2. Sensitivity analysis
3.2.1. One-way sensitivity analysis
The one-way sensitivity analysis for 5% variations in the price
of BRV shows it is still the dominant option (Table 5).
Nevertheless, the effect is different according to each medi-
cine and the percentage increases are greater for a lowering of
the price of BRV than for an increase of the same amount (5%).
Figure 3 shows the percentage variation of the ICUR corre-
sponding to a 1% variation in price of BRV upwards or down-
wards. Thus a modification upwards of the unit percentage
point of the BRV price entails a reduction of the ICUR by 9.4%
for Eslicarbacepine, 7.9% for Lacosamide, 6.2% for Perampanel
and 1.9% for Zonisamide, whereas a modification downwards
of the unit percentage point of the price entails an increase of
the ICUR by 6.3% for Eslicarbacepine, 5.5% for Lacosamide,
5.0% for Perampanel and 1.8% for Zonisamide. (Figure 3)
Table 4. Base-case results by one patient and two years treatment.
AED Effect. QALY Cost Effect. Utility Cost ICUR ICER
Brivaracetam 0.118 1,408 7,058.8
Eslicarbazepine 0.060 1,390 7,279.7 0.058 0.018 −220.91 −12,500 −3,817
Lacosamide 0.055 1,384 7,323.7 0.062 0.023 −264.93 −11,318 −4,242
Perampanel 0.066 1,390 7,384.0 0.052 0.018 −325.23 −18,085 −6,250
Zonisamide 0.034 1,399 8,137.1 0.084 0.008 −1,078.35 −128,482 −12,827
Figure 2. Incremental cost effectiveness ratio ICER and incremental cost utility ratio ICUR.
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3.2.2. Multivariate sensitivity analysis
The Monte Carlo simulation for the increase of QALYs com-
pared to the increase in cost shows the results of the multi-
variate sensitivity analysis (�Figure 4Figure 3), where the points
are largely in the lower right quadrant and always below the
acceptability threshold. This means that BRV achieves greater
utility and lower costs than the alternatives, implying it would
be the dominant option�(Figure 5).
An additional path to the cost utility plane when present-
ing the results of a probabilistic sensitivity analysis is to draw
up the cost utility acceptability curve, which is a graphical
representation of the quantification of the uncertainty around
the expected cost utility. This shows the probability of
acceptability according to the established threshold or will-
ingness to pay.
This resulted in an ICER point estimate of 20,000 Euros per
QALY gained. The sensitivity analysis determined incremental
costs to be sensitive to BRV price and the treatment effect on
treatment-response having a notable impact on the incremen-
tal QALYs. However, there were no scenarios that raised the
ICER above 20,000 Euros per QALY.
4. Discussion
This study shows the usefulness of Markov chains in the cost-
efficiency analysis of adjunctive treatment for epilepsy,
although this is extendable to other treatments. The available
data on treatment costs and use of resources derived from the
disorder are compared in the cost effectiveness analysis and
utility in the cost utility analysis. The results indicate that BRV
is a dominant option with regards to the comparators and the
sensitivity analysis places all the points in the lower right
quadrant, above all in the cost effectiveness analysis. For the
cost utility, the differences are less notable, due to the greater
presence of adverse effects presented by BRV over the
Table 5. OWA incremental cost effectiveness ratio given a 5% variation in cost
of BRV.
ICUR
Cost BRV + 5% Cost BRV −5%
Eslicarbazepine −6,646 Eslicarbazepine −18,354
Lacosamide −6,899 Lacosamide −15,739
Perampanel −12,332 Perampanel −23,838
Zonisamide −116,150 Zonisamide −140,801
Figure 3. Percentage differences in the ICUR with 1% variation in cost of BRV.
Figure 4.Q3 �PSA Cost-effectiveness plane.
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comparators. Regarding this point, it is worth considering that
not all the adverse effects detected as deriving from these
drugs were taken into account, but only the most frequent,
which gives rise to the possibility that the results would have
been different if all those detected had been introduced.
The budgetary impact study for the introduction of BRV
into the portfolio of anti-epileptic drugs for patients over 16
with POS (Barrachina et al) (2018) shows savings of 0.23% of
the cost of adjunctive treatments for epilepsy over five years.
A probabilistic sensitivity analysis performed through a Monte
Carlo simulation where all the variables introduced into the
budget impact analysis varied simultaneously estimated that
the probability of savings for the National Health Service was
84% [21].
The increasing number of treatment options and the high
costs associated with epilepsy underline the need for eco-
nomic evaluations in this field [22]. With regard to existing
cost effectiveness and cost utility studies for epilepsy treat-
ments, it is very difficult to compare results due to the differ-
ent models used in the economic evaluations and the
different parameters employed in the studies [23].The results
in the present study were represented analyzing studies using
the recommended methodologies that discuss the effective-
ness and costs.
Cost evaluation is very important in benefiting patients,
allowing healthcare costs payers to be well aware of their
options. The treatment for patients with drug-resistant epi-
lepsy should manage to render them seizure-free, avoid treat-
ment-related adverse effects, and allow the individual to
become a participating and productive member of society. In
this paper effectiveness and cost data were obtained from the
literature, but also included other healthcare costs derived
from each health status, while most cost effectiveness analyses
restrict the scope of costs to drugs
The available AEDs and utility values directly related to the
treatment used were modeled, but the indirect costs and
other clinically important epilepsy attributes (e.g.,seizure
severity, side-effects of crisis) and patient adherence in terms
of each treatment convenience in refractory patients, are miss-
ing [23].
Regarding the methodology used in the present study, it
could be said that other authors [24] have concluded that
decision trees and Markov models both behave in a similar
way and that the differences between them are very small.
However, they considered that a decision tree is more suitable
for generalized samples learned in a specific context, while
a Markov model is more suitable when the exact learning
sample must be recalled. Moreover, a decision tree may some-
times generate false suggestions.
As in the current study, Kotirum et al (2017) [25]developed
a decision tree combined with a Markov model to simulate
costs and health outcomes covering a lifetime horizon in
societal and healthcare payer perspectives. However, unlike
the present study, a multivariate probabilistic sensitivity ana-
lysis (PSA) was also conducted by these authors to simulta-
neously examine the effects of all parameter uncertainty using
a Monte Carlo simulation, although some studies have shown
that Markov models are not sensitive to the uncertainty in the
associated transition probability matrices [26].
On the other hand, Swalow et al (2017) [27] conducted
a study on the propensity for enrollment in the BRV versus
levetiracetam trials, using a different approach than our
method, and estimates a multivariate logistic regression
model where baseline characteristics were independent vari-
ables. Several propensity score models were evaluated for
model fit. The referred study showed that placebo arm differ-
ences in adjunctive BRV and levetiracetam epilepsy drug trials
indicate the presence of unobserved confounding factors
associated with placebo response. However, other studies
show that the estimated Markov switching models result in
a superior statistical fit relative to the standard (single-state)
multinomial logit models [28] and that the choice probabilities
computed by the Markov chain-based model are a good
approximation to the true choice probabilities for any random
utility-based choice model under mild conditions.
Hawkins et al (2005) [29] evaluated the decision model
developed for the National Institute for Clinical Excellence
Figure 5.Q4 �Acceptability curve for one patient comparing BRV versus each alternative treatment.
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(NICE) in the United Kingdom, comparing the long-term cost
effectiveness of drugs licensed in adults. Benefits were
assessed in terms of QALYs. Costs and benefits were dis-
counted at 6% and 1.5%, respectively, per annum, the NICE
proposal. In the present study we discount at 3% as the
Washington Panel proposes and also discount costs, reduced
number of seizures and QALYS at the same rate [30].
Unlike our study, Hawkins et al took into account for the
analysis of the full range of pharmaceutical therapies feasibly
used in the UK health system. In the case of our present study,
only the most used drugs in Spain have been selected for
comparison with BRV [31], as do other authors [32].
The results of the present study, which shows a higher cost
effectiveness ratio than utility cost, is not uncommon in eco-
nomic evaluation studies [19,[33,34]
In addition, this may be due to the ability of the QALYs to
capture the impact of adverse effects. Considering the adverse
effects causes the utility of the treatments to vary, due to
which the results obtained when comparing cost effectiveness
differ from those of cost utility. Therefore, it must be taken
into account that the adverse effects of the treatments con-
sidered in this study are those that are the most common in
the drugs selected for comparison [35–37]. In that sense,
authors like Sherina et al (2017) [38] obtain results in which
epilepsy is associated with not only seizures but also a variety
of serious co-morbidities and therefore, as other complications
increase, the expenditure will also increase, although the cost
due to adverse events is higher with older AED’s than newer
drugs.
In this regard and in relation to our results in cost effec-
tiveness and cost utility, the same authors obtain results indi-
cating that older drugs are equally efficacious as compared to
the newer in controlling seizure frequency and improving the
quality of life, but are more cost effective.
Finally, it should be noted that authors such as Charokopou
et al (2019) [15] warn that although the results of their net-
work meta-analysis based on 65 published RCTs of BRV and
other AEDs in patients with focal seizures would appear to
show the relative equivalence in efficacy, safety, and tolerabil-
ity outcomes of the included AEDs, it must be kept in mind
that, due to the inability of network meta-analysis in epilepsy
to capture unmeasured confounding factors and population
heterogeneity, network meta-analysis should not be the sole
basis for comparative treatment recommendations. Healthcare
policymakers might also consider real-world experience to
mitigate study generalizability concerns, and an individualized
treatment approach to alleviate the approach of pooling
populations together in clinical studies, to which the present
study tries to contribute.
4.1. Limitations
The limitations of these studies are the lack of real-life com-
parative data, with most of the data estimated [22]. Although
these estimations are modeled, they can over- and under-
estimate probabilistic values using the healthcare payer per-
spective. More real-life data can give us additional information
of costs. The indirect costs (productivity, concentration,
patient-time loss, and the subjective resources of each patient)
taking into account the physician and patient perspective, are
not always used to analyze cost effectiveness/utility. Neither
are the treatment costs for adverse effects considered. Much
uncertainty is associated with decisions by patients and phy-
sicians to change AEDs therapies. Physicians should perform
Quality of Life (QoL) studies from the patient’s real-life data.
These could be a key factor in physician-patient relationship,
and a tool to help the physician analyze the real overall effect
of the patient-therapy, not only over disease effects but others
in his/her life, giving us a patient-physician perspective.
Most of the limitations of studies of chronic diseases, with
probabilities of crisis with no explanation, come from the
uncertainty of results depending on each patient. It is difficult
to create a function/algorithm that represents all the patients’
pool, especially if the data come from pivotal trials that are
done in clinical trial-controlled conditions [27]. This is one of
the limitations and reasons why more studies with real data
(e.g. post-marketing) are important to help decision-making
positions (physicians, healthcare policies, etc.) support their
choice [39].
Further research and time is needed to be able to make real
world data available, extrapolated to values that can model
real-life observations. The economic evaluation of all perspec-
tives (the healthcare payer, pharmaceutical, physicians and
patients) would be the best approach. The major limitations
on cost effectiveness/utility studies are the data, perspectives,
and methodologies available. Each value that is modeled
through a cascade of methodologies incorporates an error
from each of these. More studies with new data and meth-
odologies are being analyzed [40].
5. Conclusions
The Markov chains model is useful for the cost effectiveness
and cost utility analysis of BRV compared with the following
AEDs: Eslicarbacepine, Lacosamide, Perampanel and
Zonisamide. This analysis has shown that from the point of
view of both the ICER and the ICUR, BRV is the ‘dominant
option’, indicating that BRV has more utility and less cost
compared to the other treatments. The difference was more
marked with Zonisamide than the other three comparators.
This conclusion was corroborated with the PSA, which sup-
ported the strength of the study, as the results are similar to
the cost utility analysis. The model could include other possi-
ble AEDs as comparators and assess switch sequences
between the AEDs.
The acceptability curve is a useful tool for making decisions
and assigning available resources to financing the cost effec-
tive alternatives, although it does have the limitation of not
being able to distinguish different combined distributions of
costs and incremental results of the options being compared.
Ultimately, the results show that the incremental QALYs
come at an acceptable incremental cost when employing the
commonly accepted payer willingness-to-pay threshold of
20,000 Euros per QALY gained (acceptability curve).
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